News Articles

European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC CAMBRIDGE, Mass. & OSAKA, Japan -Sunday 12 April 2020

– Approval Based on Positive Results from the Phase 3 ALTA-1L Trial Showing ALUNBRIG Demonstrated Superior Overall and Intracranial Effectiveness over Crizotinib in the First-line Setting – – Expanded Indication Provides Additional First-Line Treatment Option for the Approximately...

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy -Wednesday 8 April 2020

(BUSINESS WIRE)-- Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with...

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide,... -Monday 6 April 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for the extension of the marketing authorization of ADCETRIS®...

Takeda Adopts Executive Compensation Recoupment Policy -Friday 3 April 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced that its Board of Directors approved an executive compensation recoupment policy (“clawback policy”). The adoption of the clawback policy is part of Takeda’s ongoing efforts to...

The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate -Thursday 19 March 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that The Lancet published two papers related to Takeda’s dengue vaccine candidate (TAK-003), reporting on results from the 18-month analysis of the ongoing pivotal Phase 3 Tetravalent...

Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial -Wednesday 11 March 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple...

Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19 -Monday 9 March 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with...

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell... -Saturday 7 March 2020

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients – – Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy...

Takeda Completes Sale of Select OTC and Non-Core Assets to Acino -Friday 6 March 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa...

Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD -Thursday 5 March 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical...

Takeda Completes Sale of Select OTC and Non-Core Assets to STADA -Wednesday 4 March 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”) for a total value of $660 million USD. The portfolio includes...

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac... -Saturday 29 February 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that it has acquired PvP Biologics, Inc. following the conclusion of a Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac...

Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in... -Friday 28 February 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a subcutaneous (SC) formulation of the gut-selective...

Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for... -Friday 28 February 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Application (sNDA) to expand the use of ALUNBRIG (brigatinib) as a first-line...

Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with... -Friday 14 February 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab...

Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive... -Saturday 8 February 2020

Demonstrating business momentum with FY2019 Q3 year-to-date (YTD) revenue 2,519.5 billion yen, up +82.6% versus prior year due to acquisition of Shire and continued strong performance of 14 global brands; while Underlying Revenue expected to recover in Q4 resulting in flat to slightly...

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance... -Wednesday 5 February 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that nine hematology abstracts are being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020. The data being presented...

Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running -Wednesday 22 January 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies...

Takeda to Outline Progress on Business Transformation and Priorities at the 38th Annual J.P. Morgan Healthcare... -Wednesday 15 January 2020

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) will provide an update on the progress of its business transformation and priorities today at the 38th Annual J.P. Morgan Healthcare Conference. President and Chief Executive Officer, Christophe Weber,...

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies... -Wednesday 11 December 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by...